We assessed the frequency of programmed death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) in a cohort of 522 sarcomas from 457 patients, incuding a subset of 46 patients with 63 matched samples from local recurrence or metastases with primary tumours and/or metachronous metastases. We also investigated the correlation of PD-L1 with the presence and degree of tumour-infiltrating lymphocytes (TILs) in a subset of cases. IHC was performed using the PD-L1 SP263 companion kit (VENTANA) on tissue microarrays from an archival cohort. Evaluation of PD-L1 and TILs was performed on full sections for a subset of 23 cases. Fisher's exact and Mann Whitney test were used to establish significance (P <0.05). PD-L1 positive expression (≥1%) was identified in 31% of undifferentiated pleomorphic sarcomas, 29% of angiosarcomas, 26% of rhabdomyosarcomas, 18% of myxofibrosarcomas, 11% of leiomyosarcomas and 10% of dedifferentiated liposarcomas. Negative expression was present in all atypical lipomatous tumous/well-differentiated lipoasarcomas, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas, and Ewing sarcomas. PD-L1 IHC was concordant in 81% (38 of 47) of matched/paired samples. PD-L1 IHC was discordant in 19% (9 of 47 matched/paired samples), displaying differences in the proportion of cells expressing PD-L1 amongst paired
Introduction
The PD-1/PD-L1 axis (Programmed death 1 or CD274/ programmed death-ligand 1) plays a crucial role in immune surveillance. PD-1 is a transmembrane protein expressed on activated T and B cells and binds to its ligands, PD-L1 or PD-L2, which are variably expressed in immune (T and B cells, dendritic cells, mast cells) and nonimmune (e.g. endothelial) cells including tumour cells. The PD-1/PD-L1 axis acts as an immune checkpoint by inhibiting T-cell function leading to tumour immune escape (Reviewed in (1, 2) ). Therapeutic blockage of the PD-1/PD-L1 receptor-ligand can result in durable clinical responses in lung and bladder cancer (2-6) but their benefit in various sarcoma subtypes remains unknown, with no phase 3 studies yet published.
The frequency of PD-L1 expression in sarcomas reported in the literature is highly variable with incidences ranging from 0% to 65% (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . In their analysis, some of these series have combined statistical analysis of the two molecularly characteristic groups of sarcomas, that is those associated with recurrent specific genetic events (e.g. translocations or amplification) known to drive tumorogenesis (e.g. t(X;18)(p11.2; q11.2) in synovial sarcoma) and sarcomas with complex karyotype (e.g. myxofibrosarcoma), which lack detectable recurrent gene alterations, as a single entity (20) (21) (22) (23) . Such distinction is fundamental as sarcomas across the different groups and within the same group show distinct clinical behaviour.
The predictive and prognostic significance of PD-L1 expression in sarcomas has also been reviewed including its correlation with PD-1 expression, and the presence and degree of tumour-infiltrating lymphocytes (TILs) (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
The aims of our study were threefold. To review the incidence of PD-L1 expression in a cohort of 522 selected bone and soft tissue sarcomas from 457 patients with the commercially available and widely used PD-L1 companion kit SP263 (Ventana) (24) . This immunohistochemical assay in other tumour types (i.e. lung and urothelial) can identify patients more likely to benefit from treatment with anti-PD-[L]1 immunotherapy such as durvalumab, pembrolizumab and nivolumab. Only few studies using the clone SP263 have been published in sarcoma patients (10, 18) . A second aim was to review the level of concordance in PD-L1 expression in matched sarcoma samples from primary tumour and its recurrence and/or metastasis (or metachronous recurrent/metastatic episodes). The purpose was to identify whether changes in PD-L1 expression occur during the evolution of more aggressive sarcomas as if so, these may impact treatment of refractory advanced disease. Lastly, we correlated PD-L1 expression with the presence and degree of TILs identified on H&E sections for a subset of cases. The significance of TILs identified on routine H&E sections in sarcomas has not been widely investigated. Pathology laboratory in a 10-year (2008-2018) period of time to identify a cohort of selected bone and soft tissue sarcomas. These were diagnosed by pathologists with sarcoma expertise following standardised diagnostic criteria (20) , which included the used of FISH probes (Break-apart: SS18, EWSR1, FOXO1, DDIT3, FUS; and enumeration: MDM2) when required for tumour classification. As this is a de-identified cohort, follow-up is not available. Ewing sarcomas were the only primary bone tumours included in this cohort, all of which had an associated soft tissue component not requiring prior decalcification. Only formalin-fixed paraffin-embedded (FFPE) tissue blocks with adequate viable tumour from resection specimens were selected for construction of tissue microarrays (TMAs). Replicate tissue microarray (TMA) cores were taken from each sample (2x1 mm cores). For PD-L1 IHC, paraffin blocks were sectioned at 4 μm on to Superfrost Plus slides and stained with the Ventana PD-L1 SP263 rabbit monoclonal primary antibody (Assay v1.00.0001), using the VENTANA OptiView DAB IHC Detection Kit and the BenchMark ULTRA platform. IHC was performed on TMAs for the entire cohort and on full sections for a subset of cases (n=23). Positive (normal placenta as described (25) and negative controls were included in each run. Positive PD-L1 expression in the tumour cells was scored semiquantitatively as 0-3+, based on weak, moderate and strong membranous staining, respectively and the percentage of tumour cells expressing the protein was recorded. Following standard guidelines as per lung for the clone SP263 (24), PD-L1 expression was regarded as positive if complete or incomplete membranous expression was present in ≥1% of the tumour cells regardless the intensity. PD-L1 expression on immune cells (lymphocytes and/or plasma cells) was also recorded when identified. Although we aimed to score PD-L1 on 100 viable tumour cells, this was not achievable for sarcomas with low cellularity on TMAs. Nevertheless, standardised criteria for PD-L1 scoring, including the minimal number of cells for PD-L1 expression, in the context of sarcoma samples has not been universally established.
Materials and Methods
Evaluation of TILs was performed on 2 to 3 representative full H&E sections (4 microns in thickness) per each case only for the sarcoma subtypes with the largest number of cases (UPS, MFS and LMS) and for the metastatic/recurrent samples (Met/Rec cohort: n=306). TILs were scored following the recommendations by the International TILs Working Group for breast cancer (31) . Briefly, the intratumoural area occupied by stromal TILs was expressed as a percentage. TILs were assessed in areas away from necrosis. Tertiary lymphoid structures and other inflammatory cells (i.e. neutrophils and histiocytes) were excluded. The level of TILS was regarded as nil (0%), minimal (1-10%), intermediate (>10% and <50%) and high (>50%). These cut-offs were selected following the groups A-C of Salgado et al (26) (27) , with the exception that for this study, absent TILs (0%) was differentially recorded from mild TILs (1-10%). A limitation of applying this system to sarcomas is that, contrary to breast cancer, the tumour boundary in a proportion of sarcoma subtypes is not well defined.
For statistical analysis the Fisher exact test for a 2 x 2 contingency table and the Mann
Whitney test were used to establish significant correlations between PD-L1 and TILs with significance determined at P value: <0.05. An online calculator was used for the analysis: https://www.socscistatistics.com/tests/fisher/default2.aspx and https://www. socscistatistics. com/tests /mannwhitney/.
RESULTS

Overall cohort
The entire cohort assessed for PD- L1 Ewing sarcomas (ES, n=14) and pleomorphic liposarcomas (n=11). From this cohort, 63 samples were derived from recurrent/metastatic specimens (plus residual disease for a few of these cases, Table I ) referred to as Rec/met cohort, from 46 patients. In the overall cohort, PD-L1 positive expression (≥1%) was identified in 31% UPSs 
Rec / Met cohort
This includes paired samples from the following types: MFS (n=17), UPS (n=5), LMS (n=11), RMS (n=2), ML (n=2), pleomorphic LPS (n=2), angiosarcomas (n=3), SS (n=2), ES (n=1) and DD-LPS (n=1; Table 1 ). The median interval between acquisitions of paired lesions was variable (Range 0-6 years, Table 1 ). All paired samples including residual disease and those occurring <1 year apart were derived from independent surgical procedures ( Table 1) in the metastatic/recurrent site compared to the primary tumour in 6 of 9 cases (67%), from which 3 cases had only a modest increase (i.e. 1% to 5 or to 10%; Table 1 ) but a dramatic increase was identified in the 3 remaining cases (Figure 2) . These included a uterine leiomyosarcoma with original PD-L1 expression of 1%, which increased to 90% in its lung metastasis (Figure 2A-D) , a pleomorphic rhabdomyosarcoma from the spermatic cord with increase from 40% to 80% in the brain metastasis (Figure 2I-L) and a high-grade MFS with increase from 5% to 70% in the recurrence (Figure 2E-H 
TIL correlations
Correlation between PD-L1 expression and the presence and degree of TILs was investigated on full H&E sections exclusively on the sarcoma subtypes with the highest number of cases (MFS, UPS and LMS) and for the Mets/Rec cohort (Table 1) . MFSs and UPSs were combined for the analysis as it has been shown that these appear to represent one single biological entity within a phenotypic spectrum (21 
In the Met/Rec cohort, no correlation was identified between PD-L1 expression and
TILs including those cases associated with apparent gain of PD-L1 in the metastatic or recurrent deposit ( Table 1 ). An inverse correlation was identified in one of the three cases with significantly higher PD-L1 expression in the metastasis (pleomorphic RMS), as this showed absent TILs in the brain metastasis but high expression in the primary tumour, whereas PD-L1 expression was higher in the metastasis compared to the primary tumour (80% vs. 40%, respectively; Figure 2I-L) . The other paired cases showed no TILs at initial presentation and remained absent in the metastatic/recurrent disease ( Table 1) . Lastly, in this Met/Rec cohort, changes in the histomorphological features were also assessed between primary tumours and their matched recurrent/metastatic samples on full H&E sections to determine whether gain in PD-L1 and the metastatic/recurrent site was associated with changes in the morphology of the primary tumour. Although some samples showed changes, a significant trend was not observed.
Discussion
There are several well-described factors which account for the variability in the reported expression of PD-L1 in lung adenocarcinomas and sarcomas (1, 18, (28) (29) (30) (31) (32) , making comparisons of the literature challenging. One of these variables is the use of Clones differ in the binding site to the PD-L1 protein: extracellular (28-8 and 22C3, SP263 and E1) vs. cytoplasmic (SP142 and E1L3N) (Reviewed in (1)) with further technical differences regarding antigen retrieval conditions, staining platforms and differential binding properties according to cell types (i.e. epithelial vs. immune). The use of inconsistent cut-offs is also a significant contributing factor to discordant PD-L1 immunohistochemical expression, and it has been shown that by adjusting predefined cut-offs this can lead to misclassification of PD-L1 status in tumour samples (30) . Finally, biological reasons also contribute to the lack of uniformity in PD-L1 expression. For instance, PD-L1 can be constitutive or inducible in response to IFN-γ released by effector T cells. Inducible PD-L1 can be affected by tumour location and prior therapy (Reviewed in(1)) including radiotherapy (33) . At the current time, there is not enough literature to address the dynamics of inducible PD-L1, as a result of therapy but if such changes occur, these may potentially provide therapeutic avenues to patients who may not initially be suitable for anti-PD-L1 therapy.
Although providing an average incidence of PD-L1 expression in our combined sarcoma cohort is not biologically relevant, in view of the different molecular signature of soft tissue sarcomas (20, 23) , PD-L1 was present in 13% of all cases in which was the protein essentially only identified in tumour cells and not in immune cells when assessed primarily on TMAs. Our study shows relatively concordant findings to those previously published with the SP263 clone on smaller number of selected sarcoma subtypes (10, 18) . In this study, we demonstrated the highest expression of PD-L1 in UPS (31%), followed by angiosarcomas (29%), RMS (26%, predominantly pleomorphic subtype), MFS (18%), LMS (11%) and DD-LPS (10%). Sarcomas uniformly negative for PD-L1 expression in our series included ALT/WDL, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas, and Ewing sarcomas. This is in line with the previous observation that PD-L1 expression is a feature of sarcomas with a complex karyotype with or without high mutation burden (18) and only seen in our cases related to the complex karyotype group (UPS, angiosarcomas, pleomorphic RMS, MFS, LMS and DD-LPS). Our results however, differ when compared with other similar studies using antibodies other than the SP263 and variable cut-offs (i.e. >2+ and >5% (12)). In some of these series, the frequency of PD-L1 expression ranges from absent (0%) with the Abcam (ab58810 and ab205921) and SP142 clones (7, 8) to low (12%: H-130 clone)(9), intermediate (26-30%: AM2653AF-N. Acris & SP263)(10, 11) and high (58% & 65% with BD Pharmingen and R&D Systems and the H-130, Santa Cruz clones, respectively (12, 13) ). Although strong correlation has been established for some clones (i.e. SP263 and 22C3) but less for others (SP142 (18)), such comparative analyses have not been widely performed in sarcomas as opposed to lung adenocarcinomas. Our results are also discordant with studies reporting high PD-L1 expression in some specific sarcoma entities not identified in our cohort (i.e. liposarcomas (16) , myxoid liposarcomas (12), synovial sarcomas(13) and Ewing's sarcoma family of tumours (13, 34) .
We did not investigate the correlation between PD-L1 IHC expression and specific clinical pathological variables (i.e. tumour size, grade, site, patient's age, etc), as such correlation has not been previously identified (9, 14) and no obvious trend was seen in our cohort (See Table 1 paediatric osteosarcomas, demonstrated that 75% of metastatic lesions but no primary osteosarcomas expressed PD-L1 (35) . The same phenomenon was observed in a case of dedifferentiated chondrosarcoma, which showed absence of PD-L1 in the primary tumour and positive expression in the metastasis (36) and this has also recently been documented in a series of metastatic renal cell carcinomas (37) . Here, we report for the first time that gain in PD-L1 protein expression can occur in the context of metastatic/recurrent myxofibrosarcoma, leiomyosarcoma and pleomorphic rhabdomyosarcoma. We demonstrated on full section analysis that the percentage of positive cells expressing PD-L1 increased in the metastatic/recurrent site compared to the primary tumour in a total of 6 of 9 cases with a particularly marked increase in 3 of those cases. Based on results of the KENOTE-010 study, patients with high PD-L1 score (>50%) have significantly increased benefit with pembrolizumab compared to those with >1%(3). Therefore, it is possible that these patients, all of which showed >50% positive cells in the metastasis/recurrence but not in the primary tumour, may have an objective treatment response. Contrary to these findings, the few comparative similar analyses between paired primary and metastatic lung carcinoma samples have identified that discrepant PD-L1 expression, when it occurs, is due to negative expression in the metastatic deposit/s compared to primary tumours (8, 27, 38, 39) . It should be noted that in some of these studies, biopsies rather than resections have been used to determine concordance and intra-tumour heterogeneity for PD-L1 has been shown to account for the apparent discordance in some of those series.
With regards to our analysis of TILs assessed on H&E sections in a subset of cases, we identified no correlation with PD-L1 expression in the Met/Rec cohort but a significant association was identified for a specific sarcoma subset, leiomyosarcomas (n=116, full subset). None of the three cases of the Met/Rec cohort with significant increase in the percentage of PD-L1 positive cells contained TILs. In fact, one of those cases had high TILs in the primary and absence in the brain metastasis (Figure 2I-L) .
Lack of TILs in brain metastases has been previously reported (38) . Our other Rec/Met paired cases showed concordant absence of TILs at initial presentation and on the metastasis / recurrence ( Table 1) . As high density TILs (specifically, CD3+/CD8+) is an independent positive prognostic factor for OS and DFS in sarcomas (10) We did not characterise subsets of TILs (ie.. CD8+, FoXP3+, etc) because this has been previously published (5, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and because our study focused on the possible relevance of TILs on histological H&E-stained sections. With regards to the correlation between PD-L1 and PD-1 expression this is conflicting with a study from the Cancer Genome Atlas Research Network demonstrating that PD-L1 mRNA does not correlate with PD-1 (21) . This has also been documented in smaller studies (7) .
Our study has a number of limitations. First of all, it is essential to emphasise that the clinical predictive value of PD-L1 protein expression assessed on tumour samples has not been widely investigated in sarcoma patients and there is currently only scanty evidence from single-arm phase 2 studies of response to PD-L1 inhibitors. Importantly, in the SARC028 trial clinical, response to checkpoint inhibitors was seen in cases even in the absence of PD-L1 expression (5) , which may indicate that PD-L1 expression may not necessarily impact treatment response. Nonetheless, 2 of the 3 patients with positive PD-L1 expression in that trial (4% in total; 3 of 70 patients with a range of sarcoma types) showed either complete or partial treatment response. This is suggestive of some predictive value of PD-L1 expression assessed in pre-treatment biopsies (5) . PD-L1 expression on the full cohort was assessed using TMAs. This was partly overcome by performing PD-L1 IHC and assessment of TILs on full sections.
There is no clinical follow-up available for our cases including a lack of details about treatment modality in the vast majority. Importantly, the cohort predominantly includes treatment-naïve sarcomas with the exception for the Met/Rec cohort. For this subset of cases, it is expected that patients were treated with conventional regimens according to sarcoma type. Hence, it is likely that they were treated following universal guidelines before clinical trials were more widely available and according to clinical stage. This would make comparative analyses reliable. Although radiotherapy has been shown to induce PD-L1 expression(33), our cases with documented postradiotherapy ( Table 1 ; n=5) showed <10% PD-L1 expression. Finally, the size of the metastatic/recurrent cohort is limited and therefore a larger number of paired samples is needed to further validate these findings. Nonetheless, paired samples are scant in most centres but comprise very valuable resource to understand the biology of sarcoma progression.
Conclusions
Overall, we conclude that the frequency of PD-L1 expression in sarcomas is limited to some sarcoma subtypes and that variable selection of clones and cut-offs contributes to the marked discrepancy across different series. We focused on the 263 companion kit as this selectively identifies patient's eligibility to anti-PD-1 and/ PD-L1 inhibitors in some other cancers. Our study showed that PD-L1 can objectively increase in a small proportion of cases in paired metastases/recurrent disease to >50% expression in the tumour cells. This suggests the possibility of treatment response to immune checkpoint inhibitors in the metastatic/recurrent setting but unlikely in the primary tumour in a proportion of cases (i.e. as PD-L1 of 1-5%). In our assessment of TILs on H&E sections, we demonstrated that PD-L1 expression in leiomyosarcomas was associated with at least moderate levels of TILs identified on H&E sections. Although the prognostic significance of this association cannot be elucidated in this study, in view of the lack of clinical follow-up, the positive correlation of TILs and PD-L1 may help to triage the LMS cases which may benefit from PD-L1 IHC. Our results indicate that LMSs with moderate TILs are significantly more likely to harbour PD-L1 expression.
